Ginkgo Bioworks Holdings, Inc.
NYSE•DNA
CEO: Dr. Jason Kelly Ph.D.
板块: Healthcare
行业: Biotechnology
上市日期: 2021-04-19
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
联系方式
市值
$515.41M
市盈率 (TTM)
-1.5
9.8
股息率
--
52周最高
$17.58
52周最低
$5.37
52周范围
排名66Top 96.8%
1.5
F-Score
改良版 Piotroski 分析
基于 6 年期基本面
疲弱 • 1.5 / 9 分
评分区间 (0-9)
8-9: 价值优异
6-7: 基本面强劲
4-5: 整体稳健
0-3: 表现疲弱
数据范围: 2020-2025
深度研究
财务数据
电话会议
财务报告
新闻
利润表
资产负债表
现金流量表
财务比率
变化率
利润表 | 过去12个月 |
|---|
无数据